Remove 2025 Remove Documentation Remove Vaccines
article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111
article thumbnail

COVID-19 has propelled the regulatory industry years ahead

pharmaphorum

The development of COVID-19 vaccines required levels of cooperation and pioneering science comparable to the Apollo space programme. Within 12 months of the outbreak, vaccines were being deployed to prevent severe infections, hospitalisation, and death. billion people have been fully vaccinated. COVID-19 vaccine tracker.

Vaccines 143
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ph. Eur. adopts revised general monographs after adding paragraph on N-nitrosamines

European Pharmaceutical Review

Priorities for 2022-2025. These included 40 experts appointed by the EPC to join the newly created Working Party on mRNA vaccines , following a call for experts issued in the summer of 2022. Approval of the Guide on the declassification of documents pertaining to the work of the Ph. Appointment of 886 experts from Ph.

article thumbnail

Professor Klaus Meier on the collaborative future of oncology pharmacy

Hospital Pharmacy Europe

Developments such as mRNA cancer vaccines , pharmacogenomics and personalised medicine are going to be transformative for the sector, Professor Meier says. And he draws a parallel to the Covid-19 pandemic when pharmacists played a central role when carrying out vaccinations, even in countries where this was previously unprecedented.

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” www.fiercepharma.com/manufacturing/sanofi-pumps-554m-into-new-vaccine-manufacturing-facility-eastern-france 41 Boccard. New Project: Evolutive Vaccines Facility for Sanofi.” www.boccard.com/evolutive-vaccines-facility-for-sanofi/ 42 Amgen.

article thumbnail

Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from P-I/II Trial with PDC*lung01

PharmaShots

PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer.

article thumbnail

European regulators revoke Covid-19 business continuity status

Pharmaceutical Technology

The business continuity plan was introduced in 2020 to allow European regulators to prioritise the assessment of Covid-19 therapeutics and vaccines while also handling other responsibilities. This meant Covid-19 medicines were prioritised when it came to different pharmacovigilance processes.